Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Payables (2020 - 2025)

Historic Payables for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to $1.7 million.

  • Ovid Therapeutics' Payables fell 3690.04% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 3690.04%. This contributed to the annual value of $3.2 million for FY2024, which is 1379.96% down from last year.
  • Latest data reveals that Ovid Therapeutics reported Payables of $1.7 million as of Q3 2025, which was down 3690.04% from $4.0 million recorded in Q2 2025.
  • Over the past 5 years, Ovid Therapeutics' Payables peaked at $7.1 million during Q4 2021, and registered a low of $909523.0 during Q2 2021.
  • Its 5-year average for Payables is $3.0 million, with a median of $3.1 million in 2021.
  • Per our database at Business Quant, Ovid Therapeutics' Payables plummeted by 8037.2% in 2021 and then surged by 40757.85% in 2022.
  • Ovid Therapeutics' Payables (Quarter) stood at $7.1 million in 2021, then plummeted by 72.6% to $2.0 million in 2022, then surged by 89.61% to $3.7 million in 2023, then fell by 13.8% to $3.2 million in 2024, then tumbled by 46.43% to $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q3 2025, $4.0 million for Q2 2025, and $2.0 million during Q1 2025.